NCT00013611View on ClinicalTrials.gov

Interleukin-2 Plus Antiretroviral Therapy for HIV-Infected Patients With Low CD4+ Counts (SILCAAT Study)

PHASE3CompletedINTERVENTIONAL
Enrollment

1,695

Participants

Timeline

Start Date

March 31, 2001

Primary Completion Date

January 31, 2007

Study Completion Date

January 31, 2007

Conditions
HIV Infection
Interventions
DRUG

Proleukin

Recombinant IL-2 was given at a dose of 4.5 MIU twice daily subcutaneously for 5 consecutive days every 8 weeks, in addition to antiretroviral therapy, for 6 cycles. After the first 6 cycles, additional cycles were given to either achieve or maintain the patient's CD4+ cell count goal.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

University of Minnesota

OTHER

NCT00013611 - Interleukin-2 Plus Antiretroviral Therapy for HIV-Infected Patients With Low CD4+ Counts (SILCAAT Study) | Biotech Hunter | Biotech Hunter